Arcutis Biotherapeutics Inc (ARQT)

May 7, 2025, 11:18 AM EDT - 6 days ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 6, 2025, 11:00 PM EDT - 7 days ago

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:00 PM EDT - 7 days ago

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

May 2, 2025, 4:00 PM EDT - 11 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 19, 2025, 1:41 AM EDT - 25 days ago

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Apr 17, 2025, 8:00 AM EDT - 26 days ago

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Apr 10, 2025, 4:30 PM EDT - 4 weeks ago

Arcutis Announces Chief Financial Officer Transition

Apr 2, 2025, 1:16 PM EDT - 5 weeks ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

Mar 27, 2025, 8:00 AM EDT - 6 weeks ago

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 8:16 AM EDT - 7 weeks ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

TNXP

Mar 7, 2025, 8:00 AM EST - 2 months ago

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Feb 28, 2025, 9:00 AM EST - 2 months ago

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Feb 27, 2025, 6:17 AM EST - 2 months ago

Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck

Feb 26, 2025, 2:28 PM EST - 2 months ago

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Feb 26, 2025, 8:00 AM EST - 2 months ago

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Feb 25, 2025, 10:53 PM EST - 2 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:00 PM EST - 2 months ago

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 2 months ago

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Feb 18, 2025, 4:35 PM EST - 3 months ago

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 9:15 AM EST - 3 months ago

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Jan 12, 2025, 8:30 AM EST - 4 months ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Nov 15, 2024, 8:30 AM EST - 6 months ago

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 7, 2024, 2:24 AM EST - 6 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:00 PM EST - 6 months ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Oct 23, 2024, 4:00 PM EDT - 7 months ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Oct 22, 2024, 7:36 AM EDT - 7 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

OGN TMDX

Oct 18, 2024, 8:20 AM EDT - 7 months ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Sep 25, 2024, 1:00 AM EDT - 8 months ago

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Sep 24, 2024, 8:00 AM EDT - 8 months ago

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Aug 22, 2024, 5:13 PM EDT - 9 months ago

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22, 2024, 8:00 AM EDT - 9 months ago

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 15, 2024, 12:43 AM EDT - 9 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 9:00 PM EDT - 9 months ago

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 4:00 PM EDT - 9 months ago

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 29, 2024, 7:35 AM EDT - 10 months ago

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

Jul 29, 2024, 7:30 AM EDT - 10 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Jul 22, 2024, 8:00 AM EDT - 10 months ago

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

Jul 9, 2024, 4:53 PM EDT - 11 months ago

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

Jun 10, 2024, 2:30 PM EDT - 1 year ago

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

May 14, 2024, 7:47 PM EDT - 1 year ago

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:00 PM EDT - 1 year ago

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Apr 29, 2024, 4:00 PM EDT - 1 year ago

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Arcutis Appoints David Topper as Chief Financial Officer

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

JANX VKTX AMLX MCRB RAPT RVNC

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Mar 10, 2024, 4:00 PM EDT - 1 year ago

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Mar 9, 2024, 4:00 PM EST - 1 year ago

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Mar 4, 2024, 4:00 PM EST - 1 year ago

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares